For the year ending 2025-12-31, CYCN made $2,074K in revenue. -$3,528K in net income. Net profit margin of -170.11%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 2,074 | 2,000 | ||
| Research and development | 959 | 286 | ||
| General and administrative | 6,088 | 5,342 | ||
| Impairment loss | - | 0 | ||
| Total cost and expenses | 7,047 | 5,628 | ||
| Loss from operations | -4,973 | -3,628 | ||
| Interest income | 128 | 208 | ||
| Gain from settlement of account payable | 0 | 363 | ||
| Gain from insurance recovery | 1,317 | - | ||
| Total other income, net | 1,445 | 571 | ||
| Net loss from continuing operations | - | -3,057 | ||
| Gain from discontinued operations | - | 0 | ||
| Net loss | -3,528 | -3,057 | ||
| Foreign currency translation adjustment loss | 0 | - | ||
| Comprehensive loss | -3,528 | - | ||
| Basic EPS | -1.11 | -1.21 | ||
| Diluted EPS | -1.11 | -1.21 | ||
| Basic Average Shares | 3,181,000 | 2,518,000 | ||
| Diluted Average Shares | 3,181,000 | 2,518,000 | ||
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)